PPT-Ibrutinib for Hairy Cell Leukemia

A Brief Update of an Ongoing Trial Jeff Jones MD MPH 16 May 2015 2 P LYN BCR CD79a CD79b SYK BTK PLC γ IBRUTINIB GROWTH SURVIVAL Bcell Receptor is the Accelerator of Bcells. 1 Leukaemia and Hairy cell Leukaemia Variant Compiled on Behalf of the Clinical Task Force of the British Committee for Standards in Haematology as a revision to original guideline published Februar Ibrutinib. Sensitivity and Resistance in CLL. Y. Lynn Wang, MD, PhD, FCAP. Dept. of Pathology. University of Chicago. October 24, 2014. Outline. Ibrutinib. targets . in vivo CLL proliferation through . New agents timing?. Agne Paner, MD. Assistant professor of Medicine. RUSH University Medical Center. Blood Smear in CLL. Chronic Lymphocytic Leukemia. Most prevalent type of adult leukemia . 30% of all . Jung/. Shlush. Department . of Immunology. . Objectives of the seminar. Learn about the newest research the . . . hematopoetic. system and leukemia. Identify emerging topics and techniques. Overview. Overview (cont). Ibrutinib. -R. elated Cardiovascular A. E. s. Atrial Fibrillation. Ibrutinib-Related AF Data From 2016 ASH Conference. Wiczer et al Data. Risk Stratification. . Mechanisms of Ibrutinib-Related Cardiotoxicity. Forms a specific and irreversible bond with cysteine-481 in BTK. Highly potent BTK inhibition at . IC. 50. = 0.5 . nM. Orally administered with once daily dosing resulting in 24-hr target inhibition. Simon Rule. Professor of Clinical . Haematology. Consultant . Haematologist. Derriford. Hospital and Peninsula Medical School Plymouth. DISCLOSURES OF COMMERCIAL SUPPORT. Name of Company. Research support. Shira . Dinner, MD. Northwestern University. Educational Objectives. Define terminology used regarding leukemia. Describe . the latest developments in . the treatment of acute . lymphoblastic leukemia (ALL). (LCH) . 5 Years After B-cell Acute Lymphoblastic Leukemia in a 11 year-old boy. Professor. Ansari . Professor of pediatric hematology and oncology. Dr. Neda Ashayeri. Fellow of . of. pediatric hematology and . 11. THE LEUKEMIAS. malignancies involving lymphoid or hematopoietic cell lines . increase in circulating leukocytes (not invariable) . bone marrow always involved. replacement/hypoproliferation of normal hematopoietic cells. Josie . Montegaard. , MSN, AGPCNP-BC. Matthew S . Davids. , MD, . MMSc. . Disclosures for . Ms. . Montegaard. Advisory Committee . Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company . Consulting Agreements . Jochrys. I. . Estanislao. , MD. Pediatric Hematologist-Oncologist. Epidemiology of Childhood and Adolescent Cancer. Top 3 Cancers in Children. Hematopoietic Cancers – 40%. Acute Lymphoblastic Leukemia. Introduction to Leukemia. Definition. Historic Perspective. Etiology and Risk Factors . Incidence. Classification. Comparison of Acute and Chronic Leukemia. Leukemia. Definition. Leukemia is a malignant disease of hematopoietic tissue characterized by the accumulation abnormal white cells (neoplastic or leukemic) in the bone marrow leading to bone marrow failure, a raised circulating white cell count (leukocytosis) and infiltrate organs (e.g liver, spleen, lymph nodes, brain) . Dr Mona Yuklea. Hematology Department, Meir Hospital, 2019. CLL - incidence. The most common leukemia among adults in Western Countries. 4-6 cases /100000 person/year. At diagnosis. More than 70% of patients – older than 65 y.